Literature DB >> 9586860

Analgesia and abuse potential: an accidental association or a common substrate?

K B Franklin1.   

Abstract

The fact that centrally acting analgesics have abuse potential commensurate with their analgesic activity raises the question of whether these effects are related. The abuse potential of drugs depends on their ability to produce reinforcing effects, which are mediated by a neural system that includes the ventral tegmental dopamine cells and their connections with the ventral striatum. Morphine and amphetamine are both powerful analgesics and have high abuse potential. Their analgesic and reinforcing effects are mediated by similar receptors, similar sites of action, and overlapping neural substrates. These coincidences suggest that reinforcers may produce analgesia by transforming the aversive affective state evoked by pain into a more positive affective state. The implications of this hypothesis and its relation to other known mechanisms of analgesia are discussed. The hypothesis predicts that drugs with reinforcing effects should produce analgesia. A survey of drugs acting through 21 classes of receptors reveals that in 13 classes there is evidence for both analgesic and reinforcing effects that are approximately equipotent. The GABA(A) agonists were found to be the only drugs with confirmed abuse potential that lack analgesic activity. The interpretation of this and several other anomalous cases is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9586860     DOI: 10.1016/s0091-3057(97)00535-2

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  20 in total

Review 1.  Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review.

Authors:  Laura L Hurley; Robert E Taylor; Yousef Tizabi
Journal:  Neurotox Res       Date:  2011-09-20       Impact factor: 3.911

Review 2.  Corticolimbic circuitry in the modulation of chronic pain and substance abuse.

Authors:  Anna M W Taylor
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-05-10       Impact factor: 5.067

Review 3.  Alcohol dependence as a chronic pain disorder.

Authors:  Mark Egli; George F Koob; Scott Edwards
Journal:  Neurosci Biobehav Rev       Date:  2012-09-11       Impact factor: 8.989

Review 4.  Multigenerational and transgenerational effects of paternal exposure to drugs of abuse on behavioral and neural function.

Authors:  Lisa R Goldberg; Thomas J Gould
Journal:  Eur J Neurosci       Date:  2018-07-20       Impact factor: 3.386

5.  Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats.

Authors:  Mary C Olmstead; Lindsay H Burns
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

Review 6.  Pain and emotion: a biopsychosocial review of recent research.

Authors:  Mark A Lumley; Jay L Cohen; George S Borszcz; Annmarie Cano; Alison M Radcliffe; Laura S Porter; Howard Schubiner; Francis J Keefe
Journal:  J Clin Psychol       Date:  2011-06-06

7.  Days with pain and substance use disorders: is there an association?

Authors:  Mark J Edlund; Mark D Sullivan; Xiaotong Han; Brenda M Booth
Journal:  Clin J Pain       Date:  2013-08       Impact factor: 3.442

8.  Separating analgesia from reward within the ventral tegmental area.

Authors:  E Schifirneţ; S E Bowen; G S Borszcz
Journal:  Neuroscience       Date:  2014-01-13       Impact factor: 3.590

9.  Affective analgesia following muscarinic activation of the ventral tegmental area in rats.

Authors:  Robert G Kender; Steven E Harte; Elizabeth M Munn; George S Borszcz
Journal:  J Pain       Date:  2008-04-03       Impact factor: 5.820

10.  Inhibition of the morphine-induced rewarding effect by direct activation of spinal protein kinase C in mice.

Authors:  Kousei Oe; Minoru Narita; Satoshi Imai; Masahiro Shibasaki; Chiharu Kubota; Akiko Kasukawa; Mami Hamaguchi; Yoshinori Yajima; Mitsuaki Yamazaki; Tsutomu Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.